{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-078453","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2026-06-29T10:30:58+00:00","discovered_at":"2026-06-29T10:35:00.259312+00:00","generated_at":"2026-06-29T10:35:14.735868+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Theravance Biopharma to be acquired by Zymeworks for $17.00/share cash plus CVR","bullets":["Shareholders receive $17.00/share cash (~$929M equity value) plus a CVR for 80% of net proceeds from ampreloxetine monetization over ten years.","Transaction represents a 22% premium to TBPH's March 3, 2026 close and 10% premium to VWAP since then.","Merger expected to close in H2 2026, subject to shareholder vote (2/3 majority), HSR clearance, and customary conditions.","Termination fees: $32.515M payable by either party under certain circumstances.","Parent's debt financing commitment from OMERS Life Sciences; no financing condition for closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-078453","json":"https://secwatch.observer/filing/0001104659-26-078453.json","markdown":"https://secwatch.observer/filing/0001104659-26-078453.md","text":"https://secwatch.observer/filing/0001104659-26-078453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926078453/0001104659-26-078453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926078453/tm2619064d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T10:35:14.735868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}